Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TGFβ1-IN-3 is a diarylhydrazone derivative with inhibitory effects on fibroblast activation and proliferation.TGFβ1-IN-3 is a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 195.00 | |
5 mg | In stock | $ 483.00 | |
10 mg | In stock | $ 692.00 | |
25 mg | In stock | $ 1,080.00 | |
50 mg | In stock | $ 1,490.00 | |
100 mg | In stock | $ 1,970.00 | |
500 mg | In stock | $ 3,930.00 |
Description | TGFβ1-IN-3 is a diarylhydrazone derivative with inhibitory effects on fibroblast activation and proliferation.TGFβ1-IN-3 is a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF). |
In vitro | TGFβ1-IN-3 (compound 44) inhibitory NIH-3T3 cells with IC50 was 0.57 μM. TGFβ1-IN-3 (10 μM; 24 h) inhibits TGF-β1-induced abnormal activation of NIH-3T3 and A549 cells, as well as migration and epithelial-mesenchymal transition (EMT) of A549 cells. TGFβ1-IN-3 binds to STAT3 and is able to interact with Ile659, and the hydrophilic group piperidine formed intermolecular forces with Ser636, Arg609, and Pro639. The nitrofuran of TGFβ1-IN-3 could interact with Lys658.[1] |
In vivo | TGFβ1-IN-3 (compound 44) (30-60 mg/kg; p.o.; once daily; 22 days; C57BL/6 mice) slows the progression of IPF and improves mouse lung function. TGFβ1-IN-3 could reverse pulmonary fibrosis in a treatment model.[1] |
Molecular Weight | 442.51 |
Formula | C23H30N4O5 |
CAS No. | 2883813-58-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (101.69 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TGFβ1-IN-3 2883813-58-7 Others inhibitor inhibit